troglitazone has been researched along with Spinal Cord Injuries in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, J | 1 |
| Li, B | 1 |
| Chen, JW | 1 |
| Jiang, SD | 1 |
| Jiang, LS | 1 |
1 other study available for troglitazone and Spinal Cord Injuries
| Article | Year |
|---|---|
Spinal cord injury causes bone loss through peroxisome proliferator-activated receptor-γ and Wnt signalling.
Topics: Adipogenesis; Anilides; Animals; Bone and Bones; Bone Density; Bone Resorption; Cell Differentiation | 2012 |